Table 1 Baseline clinical characteristics
Variable | AVS+IR group | AVS–IR group | Control group | P Value§ |
|---|---|---|---|---|
(n = 28) | (n = 29) | (n = 28) | ||
Age, y | 70 ± 7 | 71 ± 8 | 70 ± 9 | 0.93 |
Female, n (%) | 13 (46) | 9 (31) | 9 (32) | 0.41 |
Body mass index, kg/m2 | 25 ± 3*†| 22 ± 2 | 23 ± 3 | 0.004 |
Waist circumference, cm | 91 ± 8*†| 84 ± 7 | 84 ± 10 | 0.003 |
Systolic blood pressure, mm Hg | 126 ± 13 | 122 ± 15 | 123 ± 18 | 0.65 |
Diastolic blood pressure, mm Hg | 77 ± 7 | 75 ± 7 | 77 ± 14 | 0.39 |
Heart rate, beats/min | 66 ± 10 | 65 ± 10 | 63 ± 6 | 0.49 |
Metabolic syndrome, n (%) | 7 (25)* | 3 (10) | 1 (4) | 0.042 |
Number of metabolic syndrome components | 1.9 ± 0.9*†| 1.3 ± 0.8 | 0.9 ± 0.9 | 0.001 |
Estimated glomerular filtration rate, mL/min | 69 ± 17 | 68 ± 13 | 75 ± 15 | 0.19 |
Fasting glucose, mmol/L | 6.5 ± 1.8*†| 5.7 ± 0.8 | 5.3 ± 0.5 | 0.001 |
Fasting insulin, μIU/mL | 8.9 (7.5–10.7)*†| 4.4 (3.5–5.3) | 3.9 (2.9–5.2) | < 0.001 |
Total cholesterol, mg/dL | 198 ± 33 | 206 ± 31 | 197 ± 38 | 0.52 |
Low-density lipoprotein cholesterol, mg/dL | 117 ± 25 | 121 ± 28 | 112 ± 30 | 0.48 |
High-density lipoprotein cholesterol, mg/dL | 60 ± 13 | 71 ± 15 | 66 ± 27 | 0.11 |
Triglycerides, mg/dL | 113 (89–142) | 95 (74–137) | 109 (84–179) | 0.32 |
High-sensitivity C-reactive protein, mg/L | 1.8 ± 5.2 | 1.4 ± 2.2 | 1.0 ± 1.6 | 0.66 |
Glycated hemoglobin,% | 6.2 ± 1.0* | 5.8 ± 0.5 | 5.5 ± 0.4 | 0.003 |
Total adiponectin, μg/mL | 8.2 (6.4–12.6)*†| 14.7 (8.3–19.0) | 14.4 (12.2–17.8) | 0.001 |
High-molecular-weight adiponectin, μg/mL | 6.1(4.0–12.7)*†| 11.9(4.8–16.1) | 11.5 (8.6–14.8) | 0.002 |
Leptin, ng/mL | 6.0 (2.8–9.7)*†| 3.7 (1.9–4.5) | 2.8 (1.7–3.9) | < 0.001 |
Renin angiotensin system inhibitors, n (%) | 10 (36) | 9 (31) | … | 0.71‡ |
β Blockers, n (%) | 2 (7) | 2 (7) | … | 0.92‡ |